Show Notes
In this week’s VJOncology podcast, we mark Liver Cancer Awareness Month by exploring the latest advances in hepatocellular and hepatobiliary cancers. Join Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center, New York, NY, Manon Allaire of Greater Paris University Hospitals, Paris, France, Stephen Lam Chan of The Chinese University of Hong Kong, Hong Kong, China, and Lorenza Rimassa of Humanitas University, Milan, Italy, as they discuss findings from the EMERALD-3 trial, challenges in selecting first-line therapies, the role of cirrhosis and artificial intelligence in patient management, evolving immunotherapy strategies, and emerging modalities including next-generation immune checkpoint inhibitors, antibody-drug conjugates, and cell therapies.
More from VJOncology Podcast
On this week’s episode of VJOncology podcasts, we explore advances in personalized approaches towards prostate cancer. Join Anis Hamid of Memorial Sloan Kettering Cancer Center, New York, NY, Daniel Keizman of Ichilov-Sourasky Medical Center, Tel-Aviv, Israel, Susan Halabi of Duke Cancer Institute, Durham, NC, and Andrew Armstrong of Duke University Medical Center, Durham, NC, as they discuss predictors of benefit for intensified therapy in metastatic hormone sensitive prostate cancer, a circulating tumor DNA (ctDNA)-based prognostic model in metastatic castration-resistant prostate cancer, and the association between tumor genetics, smoking and prostate cancer outcomes.
In this week’s VJOncology podcast, we are joined by Philippe Spiess of Moffitt Cancer Center, Tampa, FL, to explore the role of tumor acidity in cancer progression and immune evasion. Dr Spiess discusses how the acidic tumor microenvironment suppresses T-cell function, the potential of pH modulation to enhance antitumor immunity and improve responses to immunotherapy, and preclinical findings on tumor growth and survival. He also outlines an upcoming first-in-human trial investigating transdermal delivery of a therapy designed to modulate tumor pH, including its rationale, key safety and efficacy biomarkers, and potential role in combination with existing immunotherapies.
For this week’s VJOncology podcast, we mark Breast Cancer Awareness Month by bringing you the key updates in breast cancer. Join leading experts Zunairah Shah of Roswell Park Comprehensive Cancer Center, Buffalo, NY, Walter Weber of University Hospital Basel, Basel, Switzerland, Claudio Vernieri of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Yeon Hee Park of Samsung Medical Center, Seoul, South Korea, and Jennifer Ligibel of Dana-Farber Cancer Center, Boston, MA, as they discuss recent therapeutic and surgical advances. They explore data from the BWEL, PREPEC, DESTINY-Breast09, PALMARES-2, ASCENT-07 trials, as well as the link between GLP-1 receptor agonist therapy and breast cancer risk.
This week on VJOncology podcasts, we bring you a roundtable discussion from iwCAR-T 2026 exploring novel cellular therapy technologies in solid tumors. Join Marco Davila of Roswell Park Comprehensive Cancer Center, Kedar Kirtane of Moffitt Cancer Center, Nathan Welty of Penn Medicine, Eric Smith of Dana Farber Cancer Center, Sebastian Kobold of Ludwig Maximilian University, and Yihan Zuo of Roswell Park Comprehensive Cancer Center, as they explore novel engineering strategies and how to overcome common issues with CAR T-cell therapy in solid tumors.
In this week’s VJOncology podcast, we had the opportunity to attend the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, where we explored the latest advances across thoracic oncology. Join Tom Newsom-Davis of Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, Giulia Pasello of Institute Oncology Veneto, Padua, Italy, Alexander Spira of Virginia Cancer Specialists and US Oncology, Fairfax, VA, Mark Jeng of Memorial Sloan Kettering Cancer Center, New York, NY, and Triparna Sen, Ohio State University, Columbus, OH, as they discuss the PAPILLON and REZILIENT 3 studies, perioperative treatment in mesothelioma, advances in small cell lung cancer, and more.